Regeneron officer proposes $3.2M share sale

The notice lists 101,137,842 common shares outstanding alongside the proposed sale.

Rhea-AI Filing Summary

Regeneron Pharmaceuticals, Inc. officer Andrew J. Murphy filed a notice of a proposed sale of 4,147 common shares, with an aggregate market value of $3,204,379.85, through UBS Financial Services, Inc. on Nasdaq, approximately October 14, 2026. The notice also lists 4,174 common shares acquired from the issuer on October 13, 2026, through exercise of stock options in a net exercise.

Key Figures

Common shares proposed for sale: 4,147 shares Aggregate market value: $3,204,379.85 Common shares outstanding: 101,137,842 shares +1 more

4 metrics

Common shares proposed for sale 4,147 shares Approximate sale date: October 14, 2026

Aggregate market value $3,204,379.85 Proposed sale

Common shares outstanding 101,137,842 shares Listed in the proposed-sale information

Common shares acquired through stock-option exercise 4,174 shares Net exercise on October 13, 2026

Key Terms

Rule 144, aggregate market value, Exercise of Stock Options, Net Exercise, +1 more

5 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

aggregate market value financial

"aggregate market value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Exercise of Stock Options financial

"Exercise of Stock Options"

Net Exercise financial

"Net Exercise"

A net exercise is a way to convert stock options into shares without paying cash up front: instead of handing over money to buy the optioned shares, the holder receives only the number of shares equal to the option’s value after the company withholds a portion of shares to cover the exercise price and taxes. It matters to investors because it changes how many new shares are issued, affects dilution of existing shareholders, and alters company cash flow compared with a cash exercise.

shares outstanding financial

"number of shares or other units outstanding"

Shares outstanding are the total number of a company’s stock units held by all shareholders, including institutional investors and company insiders — think of them as the total number of slices of the company’s ownership pie. Investors use this number to calculate how much of the company each share represents, and it directly affects per-share measures like earnings per share, ownership percentage and valuation; when the slice count changes, an investor’s claim and the company’s per-share metrics change too.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many REGN shares did Andrew J. Murphy propose to sell?

Andrew J. Murphy, identified as an officer, proposed to sell 4,147 common shares with an aggregate market value of $3,204,379.85. The notice names UBS Financial Services, Inc. and Nasdaq and gives October 14, 2026, as the approximate sale date.

How did Andrew J. Murphy acquire the REGN shares?

The notice lists 4,174 common shares acquired from the issuer on October 13, 2026, through exercise of stock options, with the acquisition described as a net exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/14/2026 - 04:04 PM EDT Accepted by SEC EDGAR 10/14/2026 - 04:04 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001796226
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	REGENERON PHARMACEUTICALS, INC.
SEC File Number	000-19034
Address of Issuer	777 OLD SAW MILL RIVER ROAD TARRYTOWN NEW YORK 10591
Phone	9148477000
Name of Person for Whose Account the Securities are To Be Sold	MURPHY ANDREW J
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	4147	3204379.85	101137842	10/14/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/13/2026	Exercise of Stock Options	Issuer			4174	10/13/2026	Net Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	10/14/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/07/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for Andrew Murphy
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)